MORRISVILLE, NC/ ACCESSWIRE / November 9, 2016 / Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a Business Review and Update to discuss the results of the third quarter 2016, to be held Thursday, November 10, 2016 at 8:30 AM Eastern Time.

Live Event Information

To participate, connect approximately 5 to 10 minutes before the beginning of the event.

A webcast replay will be available for three months, beginning approximately 2 hours after the completion of the live event.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The Company is currently in a Phase 3 trial with levosimendan for that indication. For more information, visit

SOURCE: Investor Calendar